Pdl Biopharma Inc (NASDAQ:PDLI) shares traded -0.85% down during most recent session to reach at the closing price of $3.48. The stock exchanged hands 1.57 Million shares versus average trading capacity of 1.68 Million shares, yielding a market cap of $515.14 Million. Wall Street analysts covering the stock are projecting that the stock will reach $3 within the next 52-weeks. The mean target projections are based on 1 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Pdl Biopharma Inc (NASDAQ:PDLI) high price target of $3 and with a conservative view have low price target of $3.

PiperJaffray “Reinstates” Pdl Biopharma Inc (NASDAQ:PDLI) in a research note issued to investors on 12/22/16 to Overweight with price target of $4.

Additionally on 5/14/13 PiperJaffray “Initiates Coverage on” Pdl Biopharma Inc (NASDAQ:PDLI) to Neutral setting price target at $8.5 and on 3/05/13 JP Morgan “Maintained” the stock to Neutral at $6. Furthermore on 1/15/13 Credit Suisse “Downgrades” the stock to Underperform at $6.

On the other hand the company has Relative Strength Index (RSI 14) of 50.26 along with Average True Range (ATR 14) of 0.11, Consequently Pdl Biopharma Inc (NASDAQ:PDLI)’s weekly and monthly volatility is 2.86%, 3.17% respectively. The company’s beta value is at 0.63.

In terms of Buy, Sell or Hold recommendations, Pdl Biopharma Inc (NASDAQ:PDLI) has analysts’ mean recommendation of 0. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Pdl Biopharma Inc (NASDAQ:PDLI)’s minimum EPS for the current quarter is at $0.06 and can go high up to $0.06. The consensus mean EPS for the current quarter is at $0.06 derived from a total of 1 estimates from the analysts who have weighed in on projected earnings. However the company reported $0.01 earnings per share for the same quarter during last year.

Previously Pdl Biopharma Inc (NASDAQ:PDLI) reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.03. The company posted an earnings surprise of 37.5%.

Pdl Biopharma Inc (NASDAQ:PDLI)’s revenue estimates for the current quarter are $35.35 Million according to 1 number of analysts, for the current quarter the company has high revenue estimates of $35.35 Million in contradiction of low revenue estimates of $35.35 Million. For the current year the company’s revenue estimates are $122.96 Million compared to low analyst estimates of $119.05 Million and high estimates of $126.86 Million according to 2 number of analysts.

Currently Pdl Biopharma Inc (NASDAQ:PDLI)’s shares owned by insiders are 0.8%, whereas shares owned by institutional owners are 83.5%. However the six-month change in the insider ownership was recorded 0%, as well as three-month change in the institutional ownership was recorded -4.53%.

Pdl Biopharma Inc (NASDAQ:PDLI)’s trailing twelve month revenues are $221 Million, whereas its price to sales ratio for the same period is 2.33. Its book value per share for the most recent quarter is $5.16 while its price to book ratio for the same period is 0.67, as for as the company’s cash per share for the most recent quarter is $2.71, however its price to cash per share ratio for the same period is 1.28. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.